ZYME Stock Analysis: Buy, Sell, or Hold?
ZYME - Zymeworks Inc.
$27.94
-0.62 (-2.17%)
▼
5d:
-1.17%
30d:
+15.55%
90d:
+20.17%
BUY
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 07, 2026
7d
Get Alerted When ZYME Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZYME shows positive signals but monitor for confirmation. Market pricing in 19.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ZYME shows positive signals but monitor for confirmation. Market pricing in 19.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$7.71
Based on -15.9% avg growth
INTRINSIC VALUE TODAY
$4.79
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZYME is currently trading at $27.94, which is considered extended relative to its 30-day fair value range of $24.88 to $27.93. From a valuation perspective, the stock is trading at a discount (Forward PE: 35.5) compared to its historical average (68.5). Remarkably, the market is currently pricing in an annual earnings decline of 19.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ZYME is showing sideways momentum. Immediate support is located at $26.91, while resistance sits at $29.75.
Market Sentiment: ZYME has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $40.08 (+43.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZYME is showing sideways momentum. Immediate support is located at $26.91, while resistance sits at $29.75.
Market Sentiment: ZYME has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $40.08 (+43.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$24.88 -
$27.93
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
69.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.4% below Wall St target ($40.08)
Trading Range Analysis
30-Day Trading Range
$24.88 -
$27.93
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.64
(9.5%)
Support & Resistance Levels
Support Level
$26.91
Resistance Level
$29.75
Current Trend
Sideways
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
35.49
Wall Street Target
$40.08
(+43.4%)
Revenue Growth (YoY)
-91.9%
Profit Margin
-76.6%
Valuation Discount vs History
-19.7% cheaper
PE vs Historical
35.5 vs 68.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-19.7%
(market-implied from PE analysis)
1-Year Target
$25.15
(-10%)
2-Year Target
$22.63
(-19%)
3-Year Target
$20.37
(-27%)
3-Yr Target (if PE normalizes)
(PE: 35→69)
$39.32
(+41%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 35.5, Growth: -35.8%)
$20.37
(+-27%)
Base:
(SPY PE: 20.6, Growth: -35.8%)
$11.83
(-58%)
Bear:
(PE: 17.5, Growth: -35.8%)
$10.05
(-64%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 35.5 to 68.5
Stabilization Target:
$53.93
(+93.0%)
PE Expansion Potential:
+93.0%
Share & Embed Analysis
Last updated: April 29, 2026 6:11 AM ET
Data refreshes hourly during market hours. Next update: 7:11 AM
Data refreshes hourly during market hours. Next update: 7:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYME showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Jeffrey T L Smith
SELL
9310 shares
2026-01-12
Kenneth Galbraith
SELL
30424 shares
2026-01-12
Mark Hollywood
SELL
6120 shares
2026-01-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$99 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$93 | 55 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 53 HOLD |
Advanced ZYME Option Strategies
Professional options setups generated by AI based on today's ZYME price and gamma walls.
